

Polygenic score informed by genome-wide association studies of multiple ancestries and related traits improves risk prediction for coronary artery disease

Aniruddh P. Patel, MD^{1-5*}; Minxian Wang, PhD^{6*}; Yunfeng Ruan, PhD^{2,3}; Satoshi Koyama, MD, PhD^{2,3,7}; Shoa L. Clarke, MD, PhD^{8,9}; Xiong Yang, PhD⁶; Catherine Tcheandjieu, PhD¹⁰; Saaket Agrawal, BS^{2,3,11}; Akl C. Fahed, MD, MPH¹⁻⁵; Patrick T. Ellinor, MD, PhD¹⁻⁵; Genes & Health Research Team, the Million Veteran Program, Phillip S. Tsao, PhD^{8,9}; Yan V. Sun, PhD¹²; Kelly Cho, PhD⁷; Peter W. F. Wilson, MD¹²; Themistocles L. Assimes MD, PhD^{8,9}; David A. van Heel MD, PhD¹³; Adam S. Butterworth, PhD¹⁴; Krishna G. Aragam, MD¹⁻⁵; Pradeep Natarajan, MD, MMSc^{1-5#}; Amit V. Khera, MD, MSc^{2-4,15#}

Supplementary Appendix

Table of Contents

Supplementary Tables:

Table 1: GPS_{Mult} inputs and parameters

Table 2: Summary of GPS_{Mult} training and validation datasets

Table 3: Performance of polygenic scorers for CAD from Polygenic Score Catalog in the UK Biobank Study

Table 4: Baseline risk factor distributions and correlations with GPS_{Mult} in the UK Biobank Study

Table 5: Baseline characteristics according to high GPS_{Mult} in the UK Biobank Study

Table 6: Performance of polygenic scorers for CAD from Polygenic Score Catalog in the Million Veteran Program Study

Table 7: Performance of polygenic scorers for CAD from Polygenic Score Catalog in the Genes & Health Study

Table 8: Model C-statistics by ancestry in the UK Biobank Study

Table 9: Model net reclassification by ancestry in the UK Biobank Study

Supplementary Figures:

Figure 1: Sequential improvements in R^2 with GPS_{Mult}

Figure 2: GPS_{Mult} performance by sex and age subgroups

Figure 3: Equivalents of increased risk for incident coronary artery disease event identified by high GPS_{Mult}

Figure 4: Decrease in risk for incident coronary artery disease identified by low GPS_{Mult}

Figure 5: NRI for GPS_{Mult} and CAD risk enhancers over PCE 10-year risk estimates

Figure 6: Association of GPS_{Mult} and risk factors with incident and recurrent coronary artery disease events

References

Table 1: GPS_{Mult} inputs and parameters

Trait	Name	Dominant Ancestry	N Cases	N Controls	ρ	h^2 scale	Is sparse LD	Train OR/SD	Layer 1 Mixing weight	Layer 2 Mixing weight	Final Weight	Reference
CAD	CARDIO-GRAM plusC4D no UKBB	EUR	86847	417789	0.018	1	F	1.92	0.51	0.67	0.263	¹
	BBJ	EAS	29319	183134	0.01	0.7	F	1.43	0.08		0.041	²
	Genes & Health	SAS	1110	20898	0.0056	1.4	F	1.11	0.05		0.026	³
	FinnGen	FIN	33628	275526	0.0032	1.4	F	1.46	0.02		0.010	⁴
	MVP	EUR	95151	197287	0.018	0.7	F	1.72	0.23		0.120	⁵
	MVP	AFR	17202	59507	0.018	1.4	F	1.10	0.01		0.006	⁵
	MVP	HISP	6378	24270	0.0018	0.7	F	1.16	0.00		0.000	⁵
BMI	GIANT	EUR	339224		1	1	T	1.12	0.11	0.03	0.014	⁶
	BBJ	EAS	163835		0.32	0.7	F	1.06	0.05		0.007	²
DBP	MVP	EUR	249262		0.032	1.4	F	1.11	0.12	0.08	0.038	⁷
	BBJ	EAS	145515		0.01	0.7	F	1.07	0.06		0.019	²
SBP	MVP	EUR	249262		0.032	0.7	F	1.19	0.19	0.00	0.000	⁷
	BBJ	EAS	145505		0.018	1.4	F	1.09	0.05		0.000	²
DM	MVP	EUR	148726	965732	1	1.4	T	1.31	0.29	0.33	0.179	⁸
	MVP	AFR	24646	31446	0.018	0.7	F	1.06	0.00		0.000	⁸
	MVP	HISP	8,616	11,829	0.032	1.4	T	1.09	0.04		0.027	⁸

	AGEN T2D	EAS	77418	356122	0.56	1	T	1.14	0.01		0.005	⁹
	FinnGen	FIN	49303	255466	0.032	1.4	F	1.16	0.03		0.018	⁴
	Genes & Health	SAS	9044	12066	0.0056	1.4	F	1.05	0.00		0.000	¹⁰
LDL-C	GLGC	EUR	1320016		0.1	0.7	T	1.22	0.26	0.09	0.028	¹¹
	GLGC	AFR	99432		0.01	0.7	T	1.15	0.07		0.007	¹¹
	GLGC	SAS	40963		0.00032	1.4	T	1.15	0.00		0.000	¹¹
	MVP	EUR	215551		0.01	0.7	T	1.17	0.14		0.015	¹²
	MVP	AFR	57332		0.0056	0.7	T	1.13	0.05		0.005	¹²
	MVP	HISP	24742		0.0018	0.7	T	1.18	0.09		0.009	¹²
	BBJ	EAS	72866		0.0032	0.7	T	1.13	0.00		0.000	²
HDL-C	GLGC	EUR	1320016		1	0.7	T	1.24	0.07	0.06	0.009	¹¹
	GLGC	AFR	99432		0.32	1.4	F	1.08	0.00		0.000	¹¹
	GLGC	SAS	40963		0.001	1	T	1.05	0.04		0.006	¹¹
	MVP	EUR	215551		0.32	1	F	1.20	0.20		0.026	¹²
	MVP	AFR	57332		0.0056	1	F	1.07	0.00		0.000	¹²
	MVP	HISP	23946		0.056	1.4	F	1.08	0.00		0.000	¹²
	BBJ	EAS	74970		0.32	0.7	F	1.06	0.00		0.000	²
TC	GLGC	EUR	1320016		0.18	0.7	T	1.20	0.13	0.00	0.000	¹¹
	GLGC	AFR	99432		0.01	0.7	T	1.13	0.00		0.000	¹¹

	GLGC	SAS	40963	0.00018	1.4	F	1.14	0.00		0.000	¹¹	
	MVP	EUR	215551	0.01	0.7	T	1.16	0.00		0.000	¹²	
	MVP	AFR	57332	0.0056	0.7	F	1.11	0.00		0.000	¹²	
	MVP	HISP	24743	0.001	0.7	F	1.17	0.07		0.000	¹²	
	BBJ	EAS	135808	0.001	0.7	F	1.12	0.04		0.000	²	
TG	GLGC	EUR	1320016	1	0.7	T	1.24	0.24	0.00	0.000	¹¹	
	GLGC	AFR	99432	0.018	1.4	F	1.09	0.00		0.000	¹¹	
	GLGC	SAS	40963	0.01	0.7	F	1.09	0.00		0.000	¹¹	
	MVP	EUR	215551	0.18	1	F	1.19	0.00		0.000	¹²	
	MVP	AFR	57332	0.032	0.7	F	1.07	0.00		0.000	¹²	
	MVP	HISP	24063	0.018	1.4	F	1.08	0.00		0.000	¹²	
	BBJ	EAS	111667	0.056	0.7	T	1.07	0.00		0.000	²	
PAD	MVP	EUR	24009	150983	0.01	0.7	F	1.32	0.25	0.04	0.012	¹³
	MVP	AFR	5273	42485	1	1.4	T	1.07	0.05		0.002	¹³
	MVP	HISP	1925	18285	0.0032	1.4	T	1.07	0.03		0.002	¹³
	FinnGen	FIN	11924	288638	0.0056	0.7	F	1.16	0.08		0.004	⁴
	BBJ	EAS	4112	173601	0.0032	0.7	F	1.13	0.09		0.004	²
Stroke	MEGA-STROKE	EUR	40585	406111	0.0032	0.7	T	1.17	0.17	0.07	0.030	¹⁴
	BBJ	EAS	22664	152022	0.56	1.4	T	1.06	0.05		0.010	²

	GBMI	AFR	1161	24416	0.018	1.4	T	1.04	0.05		0.010	¹⁵
CKD	MVP	EUR	567460		0.0001	0.7	T	1.05	0.04	0.06	0.025	¹⁶
	MVP	AFR	13842		0.018	1	F	1.04	0.03		0.019	¹⁶
	BBJ	EAS	150266		0.0056	0.7	T	1.02	0.00		0.000	²

Traits: CAD – coronary artery disease; BMI – body mass index; DBP – diastolic blood pressure; SBP – systolic blood pressure; DM – diabetes mellitus; LDL-C – low density lipoprotein cholesterol; HDL-C – high-density lipoprotein cholesterol; TG – triglycerides; PAD – peripheral artery disease; CKD – chronic kidney disease.

Consortia: CARDIOGRAMplusC4D no UKBB – Coronary ARtery Disease Genomewide Replication and Meta-analysis plus The Coronary Artery Disease Genetics consortium excluding UK Biobank; BBJ – Biobank Japan; GIANT – Genetic Investigation of ANthropometric Traits; MVP – Million Veteran Program; AGEN-T2D – Asian Genetic Epidemiology Network Type 2 Diabetes Consortium; GLGC – Global Lipids Genetics Consortium excluding the UK Biobank; GBMI – Global Biobank Meta-analysis Initiative

Ancestries: AFR – African; EAS – East Asian; EUR – European; FIN – Finnish; SAS – South Asian

LDPred2 parameters: p – tuning parameter to model the proportion of variants assumed to be causal; h^2 scale – factor by which heritability is scaled; is sparse LD – whether a sparse linkage disequilibrium matrix is applied, if true some variant effect estimates are fit to zero. A total of 102 combinations of these three parameters were possible and led to generation of 102 polygenic scores for each input ancestry-stratified set of GWAS summary statistics. The parameters leading to the best individually performing polygenic score in predicting CAD in a training dataset of 116,649 participants in the UK Biobank were chosen, specific to each ancestry-specific GWAS.

Mixing weights: Layer 1 – weight determined from a logistic regression model predicting CAD in a UK Biobank training dataset by combining different ancestry-specific GPS from GWAS for a specific trait. Layer 2 - weight determined from a logistic regression model predicting CAD in the same UKB training dataset by combining different trait-specific scores from the Layer 1 step. Final weight - overall mixing weight incorporating proportional weights from layers 1 and 2, normalized to 100%. The final GPS_{Mult} score was a linear combination of all the input scores according to the final weight. The dataset for training the models and for estimating the mixing weight was from 116,649 participants in the UK Biobank. All the regression models for predicting CAD were adjusted for age, sex, genotyping array, and the first ten principal components of ancestry.

Table 2: Summary of GPS_{Mult} training and validation datasets

Stage	Training	Validation						
Cohort	UK Biobank	UK Biobank				MVP		G&H
Ancestry	European	African	East Asian	European	South Asian	African	European	South Asian
N	116649	7281	1464	308264	8982	33096	124467	16874
Age (SD)	57.5 (7.9)	52.4 (8.0)	53.0 (7.6)	57.3 (8.0)	53.8 (8.5)	56.1 (12.4)	60.8 (13.3)	40.6 (14.5)
Male Sex (%)	47.5%	43.5%	37.2%	45.6%	54.1%	84.1%	91.3%	45.9%
Case	4412	124	22	10492	542	4831	29171	853
Control	112237	7157	1442	297772	8440	28265	95296	16021

Baseline demographics of participants included in GPS_{Mult} training and validation. These individuals were not included in genome-wide association data used to construct GPS_{Mult}, and individuals in training and validation of GPS_{Mult} are distinct.

Table 3: Performance of polygenic scores for CAD from Polygenic Score Catalog in the UK Biobank Study

Score Name	Identifier	Publication	Beta	SE	P	OR/SD [95% CI]	Population
GRS28	PGS000200	Tikkanen E et al. Arterioscler Thromb Vasc Biol (2013)	0.27	0.29	<0.001	1.31 [1.31-1.34]	EUR
GRS27	PGS000010	Mega JL et al. Lancet (2015)	0.3	0.32	<0.001	1.35 [1.35-1.38]	EUR
GRS50	PGS000011	Tada H et al. Eur Heart J (2015)	0.29	0.31	<0.001	1.34 [1.34-1.37]	EUR
GRS49K	PGS000012	Abraham G et al. Eur Heart J (2016)	0.36	0.39	<0.001	1.44 [1.44-1.47]	EUR
CHD57	PGS000057	Natarajan P et al. Circulation (2017)	0.29	0.31	<0.001	1.34 [1.34-1.37]	EUR
GRS_CAD	PGS000019	Paquette M et al. J Clin Lipidol (2017)	0.4	0.42	<0.001	1.49 [1.49-1.52]	EUR
GPS ₂₀₁₈	PGS000013	Khera AV et al. Nat Genet (2018)	0.54	0.57	<0.001	1.72 [1.72-1.76]	EUR
metaGRS_CAD	PGS000018	Inouye M et al. J Am Coll Cardiol (2018)	0.57	0.59	<0.001	1.77 [1.77-1.8]	EUR
CHD46	PGS000059	Hajek C et al. Circ Genom Precis Med (2018)	0.24	0.26	<0.001	1.27 [1.27-1.3]	EUR
CAD_EJ2020	PGS000116	Elliott J et al. JAMA (2020)	0.42	0.44	<0.001	1.53 [1.53-1.56]	EUR
PRS_COMBINED	PGS000749	Gola D et al. Circ Genom Precis Med (2020)	0.4	0.42	<0.001	1.49 [1.49-1.52]	EUR
PRS_CHD	PGS000329	Mars N et al. Nat Med (2020)	0.5	0.52	<0.001	1.64 [1.64-1.68]	EUR
GPS_CAD_SA	PGS000296	Wang M et al. J Am Coll Cardiol (2020)	0.51	0.54	<0.001	1.67 [1.67-1.71]	EUR
PRS70_CAD	PGS000349	Pechlivanis S et al. BMC Med Genet (2020)	0.14	0.16	<0.001	1.14 [1.14-1.17]	EUR
GRS_Metabo	PGS000818	Bauer A et al. Genet Epidemiol (2021)	0.39	0.41	<0.001	1.48 [1.48-1.51]	EUR
AnnoPred _{CAD}	PGS001355	Ye Y et al. Circ Genom Precis Med (2021)	0.57	0.59	<0.001	1.76 [1.76-1.8]	EUR
metaPRS_CAD	PGS002262	Lu X et al. Eur Heart J (2022)	0.26	0.28	<0.001	1.30 [1.3-1.32]	EUR
CHD_PRSCS	PGS001780	Tamlander M et al. Commun Biol (2022)	0.55	0.57	<0.001	1.73 [1.73-1.77]	EUR
GPS _{Mult}	-	-	0.75	0.77	<0.001	2.12 [2.12-2.17]	EUR

A series of prior published scores or CAD from the Polygenic Score Catalog that did not include any UK Biobank participants in the GWAS data for score development were compared with GPS_{Mult} within the validation cohort of European ancestry individuals from the UK Biobank. The odds ratio for prevalent coronary artery disease (CAD) risk per standard deviation of the polygenic score and 95% confidence interval were assessed in a logistic regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry.

Table 4: Baseline risk factor distributions and correlations with GPS_{Mult}

	Prevalent CAD	Incident CAD	No CAD	All	Correlation
n	11180	11898	302913	325991	
LDL Cholesterol* (mg/dl, mean (SD))	143.78 (35.76)	156.08 (35.81)	145.25 (32.95)	145.60 (33.22)	0.152
HDL Cholesterol* (mg/dl, mean (SD))	46.20 (12.16)	50.49 (13.19)	56.72 (14.81)	56.13 (14.84)	-0.115
Triglycerides* (mg/dl, median [IQR])	170.17 [118.87, 243.84]	167.25 [117.68, 241.03]	131.98 [92.65, 192.47]	134.37 [93.98, 196.19]	0.108
Systolic Blood Pressure (mm Hg, mean (SD))	140.00 (19.86)	147.28 (20.06)	139.37 (19.56)	139.68 (19.64)	0.081
Diastolic Blood Pressure (mm Hg, mean (SD))	78.94 (10.93)	84.57 (10.94)	82.27 (10.66)	82.24 (10.71)	0.071
Body-mass Index (kg/m², mean (SD))	29.13 (4.77)	28.58 (4.79)	27.26 (4.74)	27.37 (4.76)	0.108
Diabetes Mellitus# (%)	2197 (19.7)	1460 (12.3)	14012 (4.6)	17669 (5.4)	0.028
Chronic Kidney Disease# (%)	1621 (15.2)	1134 (10.0)	11484 (4.0)	14239 (4.6)	0.091

The baseline variable distributions for traditional CAD risk factors stratified by CAD case status. Correlations between the GPS_{Mult} and risk factors across the entire validation population, adjusted for top 10 principal components and traditional risk factors were assessed using Pearson's correlation for continuous traits and #point biserial correlation for binary traits. The P value for each association was less than 2×10^{-12} . *LDL-C, HDL-C, and triglyceride values were adjusted for cholesterol-lowering medication status, as previously described.¹⁷ Diagnosis of diabetes was based on self-report, primary care records or hospitalization records confirming a clinical diagnosis, self-reported consumption of medications to treat diabetes, or glycohemoglobin >6.5% at enrollment and CKD was defined as eGFRcys <60 mL/min, as previously described.¹⁸ *Adjusted values if individual taking cholesterol lowering medications as described in Patel et al. *JAMA Network Open* 2020. For example, in the case of statin intake, lower density cholesterol was divided by 0.7 and triglycerides by 0.85.

Table 5: Baseline characteristics according to high GPS_{Mult}

	Bottom 80% GPS _{Mult}	Top 20% GPS _{Mult}	p
Number of individuals	224,292	56,424	
Prevalent coronary artery disease (%)	5,496 (2.5)	4,155 (7.4)	<0.001
Age, years (mean, SD)	57.5 (7.9)	57.2 (9.0)	<0.001
Male sex (%)	102,639 (45.8)	25,926 (45.9)	0.428
Hypertension (%)	58,635 (27.2)	20,305 (37.9)	<0.001
Diabetes Mellitus (%)	9,219 (4.1)	4,653 (8.2)	<0.001
*LDL cholesterol, mg/dL (mean (SD))	137.7 (33.0)	140.5 (35.9)	<0.001
*HDL cholesterol, mg/dL (mean (SD))	57.0 (14.9)	53.9 (14.3)	<0.001
*Triglycerides, mg/dL (median [IQR])	129.4 [91.6, 186.8]	142.3 [100.7, 204.9]	<0.001
Current smoking (%)	20,365 (9.1)	5,866 (10.4)	<0.001
Family history of heart disease (%)	95,049 (42.4)	29,936 (53.1)	<0.001
Body mass index, kg/m ² (mean (SD))	27.2 (4.7)	28.1 (5.0)	<0.001
Lipid-lowering therapy (%)	31,201 (13.9)	13,892 (24.6)	<0.001

Baseline characteristics according to high GPS_{Mult} status, defined as the top 20% of the distribution empirically shown to be at ≥ 3 -fold risk of coronary artery disease. LDL: low-density lipoprotein; HDL: high-density lipoprotein. *LDL-C, HDL-C, and triglyceride values were adjusted for cholesterol-lowering medication status, as previously described.¹⁷

Table 6: Performance of polygenic scores for CAD from Polygenic Score Catalog in the Million Veteran Program Study

Score Name	Identifier	Publication	Beta	SE	P	OR/SD [95% CI]	Population
GRS28	PGS000200	Tikkanen E et al. Arterioscler Thromb Vasc Biol (2013)	0.053	0.016	0.001	1.05 [1.02-1.09]	AFR
GRS27	PGS000010	Mega JL et al. Lancet (2015)	0.066	0.016	<0.001	1.07 [1.04-1.1]	AFR
GRS50	PGS000011	Tada H et al. Eur Heart J (2015)	0.073	0.016	<0.001	1.08 [1.04-1.11]	AFR
GRS49K	PGS000012	Abraham G et al. Eur Heart J (2016)	0.082	0.016	<0.001	1.09 [1.05-1.12]	AFR
CHD57	PGS000057	Natarajan P et al. Circulation (2017)	0.066	0.016	<0.001	1.07 [1.03-1.1]	AFR
GRS_CAD	PGS000019	Paquette M et al. J Clin Lipidol (2017)	0.115	0.016	<0.001	1.12 [1.09-1.16]	AFR
GPS ₂₀₁₈	PGS000013	Khera AV et al. Nat Genet (2018)	0.128	0.016	<0.001	1.14 [1.1-1.17]	AFR
CAD_GRS_204	PGS000058	Morieri ML et al. Diabetes Care (2018)	0.117	0.016	<0.001	1.12 [1.09-1.16]	AFR
metaGRS_CAD	PGS000018	Inouye M et al. J Am Coll Cardiol (2018)	0.155	0.016	<0.001	1.17 [1.13-1.21]	AFR
CHD46	PGS000059	Hajek C et al. Circ Genom Precis Med (2018)	0.060	0.016	<0.001	1.06 [1.03-1.1]	AFR
157SNP_GRS	PGS000798	Severance LM et al. J Cardiovasc Comput Tomogr (2019)	0.086	0.016	<0.001	1.09 [1.06-1.13]	AFR
CAD_EJ2020	PGS000116	Elliott J et al. JAMA (2020)	0.114	0.016	<0.001	1.12 [1.08-1.16]	AFR
PRS_DE	PGS000748	Gola D et al. Circ Genom Precis Med (2020)	0.118	0.016	<0.001	1.13 [1.09-1.16]	AFR
PRS_COMBINED	PGS000749	Gola D et al. Circ Genom Precis Med (2020)	0.112	0.016	<0.001	1.12 [1.08-1.16]	AFR
PRS_CHD	PGS000329	Mars N et al. Nat Med (2020)	0.144	0.016	<0.001	1.15 [1.12-1.19]	AFR
GPS_CAD_SA	PGS000296	Wang M et al. J Am Coll Cardiol (2020)	0.158	0.016	<0.001	1.17 [1.13-1.21]	AFR
PRS70_CAD	PGS000349	Pechlivanis S et al. BMC Med Genet (2020)	0.028	0.016	0.0812	1.03 [1-1.06]	AFR
MetaPRS _{CAD}	PGS000337	Koyama S et al. Nat Genet (2020)	0.167	0.016	<0.001	1.18 [1.14-1.22]	AFR
PRS176_CHD	PGS000899	Feitosa MF et al. Circ Genom Precis Med (2021)	0.109	0.016	<0.001	1.11 [1.08-1.15]	AFR
GRS_Metabo	PGS000818	Bauer A et al. Genet Epidemiol (2021)	0.101	0.016	<0.001	1.11 [1.07-1.14]	AFR

AnnoPred _{CAD}	PGS001355	Ye Y et al. Circ Genom Precis Med (2021)	0.161	0.016	<0.001	1.18 [1.14-1.21]	AFR
portability-Idpred2	PGS002048	Prive F et al. Am J Hum Genet (2022)	0.129	0.016	<0.001	1.14 [1.1-1.17]	AFR
metaPRS_CAD	PGS002262	Lu X et al. Eur Heart J (2022)	0.061	0.016	<0.001	1.06 [1.03-1.1]	AFR
PRSCS _{CHD}	PGS001780	Tamlander M et al. Commun Biol (2022)	0.166	0.016	<0.001	1.18 [1.14-1.22]	AFR
GBE_HC942	PGS000962	Tanigawa Y et al. PLoS Genet (2022)	0.088	0.016	<0.001	1.09 [1.06-1.13]	AFR
Idpred_cad	PGS002244	Mars N et al. Cell Genom (2022)	0.139	0.016	<0.001	1.15 [1.11-1.19]	AFR
PRS_2022	PGS003356	Aragam KA et al. Nat Genet (2022)	0.160	0.016	<0.001	1.17 [1.14-1.21]	AFR
GPSMult	-	-	0.222	0.016	<0.001	1.25 [1.21-1.29]	AFR
GRS28	PGS000200	Tikkanen E et al. Arterioscler Thromb Vasc Biol (2013)	0.185	0.007	<0.001	1.2 [1.19-1.22]	EUR
GRS27	PGS000010	Mega JL et al. Lancet (2015)	0.214	0.007	<0.001	1.24 [1.22-1.26]	EUR
GRS50	PGS000011	Tada H et al. Eur Heart J (2015)	0.195	0.007	<0.001	1.21 [1.2-1.23]	EUR
GRS49K	PGS000012	Abraham G et al. Eur Heart J (2016)	0.249	0.007	<0.001	1.28 [1.27-1.3]	EUR
CHD57	PGS000057	Natarajan P et al. Circulation (2017)	0.118	0.007	<0.001	1.13 [1.11-1.14]	EUR
GRS_CAD	PGS000019	Paquette M et al. J Clin Lipidol (2017)	0.273	0.007	<0.001	1.31 [1.3-1.33]	EUR
GPS_CAD	PGS000013	Khera AV et al. Nat Genet (2018)	0.370	0.007	<0.001	1.45 [1.43-1.47]	EUR
CAD_GRS_204	PGS000058	Morieri ML et al. Diabetes Care (2018)	0.326	0.007	<0.001	1.39 [1.37-1.41]	EUR
metaGRS_CAD	PGS000018	Inouye M et al. J Am Coll Cardiol (2018)	0.385	0.007	<0.001	1.47 [1.45-1.49]	EUR
CHD46	PGS000059	Hajek C et al. Circ Genom Precis Med (2018)	0.165	0.007	<0.001	1.18 [1.16-1.2]	EUR
157SNP_GRS	PGS000798	Severance LM et al. J Cardiovasc Comput Tomogr (2019)	0.289	0.007	<0.001	1.33 [1.32-1.35]	EUR
CAD_EJ2020	PGS000116	Elliott J et al. JAMA (2020)	0.295	0.007	<0.001	1.34 [1.32-1.36]	EUR
PRS_DE	PGS000748	Gola D et al. Circ Genom Precis Med (2020)	0.273	0.007	<0.001	1.31 [1.3-1.33]	EUR
PRS_COMBINED	PGS000749	Gola D et al. Circ Genom Precis Med (2020)	0.275	0.007	<0.001	1.32 [1.3-1.33]	EUR

PRS_CHD	PGS000329	Mars N et al. Nat Med (2020)	0.367	0.007	<0.001	1.44 [1.42-1.46]	EUR
GPS_CAD_SA	PGS000296	Wang M et al. J Am Coll Cardiol (2020)	0.356	0.007	<0.001	1.43 [1.41-1.45]	EUR
PRS70_CAD	PGS000349	Pechlivanis S et al. BMC Med Genet (2020)	0.104	0.007	<0.001	1.11 [1.09-1.13]	EUR
MetaPRS _{CAD}	PGS000337	Koyama S et al. Nat Genet (2020)	0.418	0.007	<0.001	1.52 [1.5-1.54]	EUR
PRS176_CHD	PGS000899	Feitosa MF et al. Circ Genom Precis Med (2021)	0.327	0.007	<0.001	1.39 [1.37-1.41]	EUR
GRS_Metabo	PGS000818	Bauer A et al. Genet Epidemiol (2021)	0.258	0.007	<0.001	1.29 [1.28-1.31]	EUR
AnnoPred _{CAD}	PGS001355	Ye Y et al. Circ Genom Precis Med (2021)	0.383	0.007	<0.001	1.47 [1.45-1.49]	EUR
portability-lpred2	PGS002048	Prive F et al. Am J Hum Genet (2022)	0.379	0.007	<0.001	1.46 [1.44-1.48]	EUR
metaPRS_CAD	PGS002262	Lu X et al. Eur Heart J (2022)	0.207	0.007	<0.001	1.23 [1.21-1.25]	EUR
PRSCS _{CHD}	PGS001780	Tamlander M et al. Commun Biol (2022)	0.372	0.007	<0.001	1.45 [1.43-1.47]	EUR
GBE_HC942	PGS000962	Tanigawa Y et al. PLoS Genet (2022)	0.287	0.007	<0.001	1.33 [1.31-1.35]	EUR
lpred_cad	PGS002244	Mars N et al. Cell Genom (2022)	0.344	0.007	<0.001	1.41 [1.39-1.43]	EUR
PRS ₂₀₂₂	PGS003356	Aragam KA et al. Nat Genet (2022)	0.477	0.008	<0.001	1.61 [1.59-1.64]	EUR
GPS _{Mult}	-	-	0.542	0.008	<0.001	1.72 [1.69-1.75]	EUR

The odds ratio for prevalent coronary artery disease (CAD) risk per standard deviation of the polygenic score and 95% confidence interval were validated in a logistic regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry in a holdout cohort of individuals of the Million Veteran Project using prior published scores from the Polygenic Score Catalog. AFR: African ancestry; EUR: European ancestry.

Table 7: Performance of polygenic scores for CAD from Polygenic Score Catalog in the Genes & Health Study

Score Name	Identifier	Publication	Beta	SE	P	OR/SD [95% CI]	Population
GRS28	PGS000200	Tikkannen E et al. Arterioscler Thromb Vasc Biol (2013)	0.169	0.040	<0.001	1.18 [1.09-1.28]	SAS
GRS27	PGS000010	Mega JL et al. Lancet (2015)	0.159	0.040	<0.001	1.17 [1.08-1.27]	SAS
GRS50	PGS000011	Tada H et al. Eur Heart J (2015)	0.108	0.039	0.006	1.11 [1.03-1.2]	SAS
GRS49K	PGS000012	Abraham G et al. Eur Heart J (2016)	0.288	0.044	<0.001	1.33 [1.22-1.45]	SAS
CHD57	PGS000057	Natarajan P et al. Circulation (2017)	0.105	0.040	0.009	1.11 [1.03-1.2]	SAS
GRS_CAD	PGS000019	Paquette M et al. J Clin Lipidol (2017)	0.218	0.040	<0.001	1.24 [1.15-1.34]	SAS
GPS ₂₀₁₈	PGS000013	Khera AV et al. Nat Genet (2018)	0.285	0.042	<0.001	1.33 [1.23-1.44]	SAS
CAD_GRS_204	PGS000058	Morieri ML et al. Diabetes Care (2018)	0.229	0.040	<0.001	1.26 [1.16-1.36]	SAS
metaGRS_CAD	PGS000018	Inouye M et al. J Am Coll Cardiol (2018)	0.327	0.044	<0.001	1.39 [1.27-1.51]	SAS
CHD46	PGS000059	Hajek C et al. Circ Genom Precis Med (2018)	0.111	0.040	0.006	1.12 [1.03-1.21]	SAS
157SNP_GRS	PGS000798	Severance LM et al. J Cardiovasc Comput Tomogr (2019)	0.244	0.041	<0.001	1.28 [1.18-1.38]	SAS
CAD_EJ2020	PGS000116	Elliott J et al. JAMA (2020)	0.327	0.042	<0.001	1.39 [1.28-1.5]	SAS
PRS_COMBINED	PGS000749	Gola D et al. Circ Genom Precis Med (2020)	0.328	0.041	<0.001	1.39 [1.28-1.51]	SAS
PRS_DE	PGS000748	Gola D et al. Circ Genom Precis Med (2020)	0.306	0.041	<0.001	1.36 [1.25-1.47]	SAS
PRS_CHD	PGS000329	Mars N et al. Nat Med (2020)	0.310	0.041	<0.001	1.36 [1.26-1.48]	SAS
GPS_CAD_SA	PGS000296	Wang M et al. J Am Coll Cardiol (2020)	0.338	0.041	<0.001	1.4 [1.29-1.52]	SAS
PRS70_CAD	PGS000349	Pechlivanis S et al. BMC Med Genet (2020)	0.072	0.040	0.069	1.08 [0.99-1.16]	SAS
MetaPRS _{CAD}	PGS000337	Koyama S et al. Nat Genet (2020)	0.428	0.042	<0.001	1.53 [1.41-1.67]	SAS
PRS176_CHD	PGS000899	Feitosa MF et al. Circ Genom Precis Med (2021)	0.251	0.041	<0.001	1.29 [1.19-1.39]	SAS
GRS_Metabo	PGS000818	Bauer A et al. Genet Epidemiol (2021)	0.209	0.040	<0.001	1.23 [1.14-1.33]	SAS

AnnoPred _{CAD}	PGS001355	Ye Y et al. Circ Genom Precis Med (2021)	0.352	0.041	<0.001	1.42 [1.31-1.54]	SAS
portability-ldpred2	PGS002048	Prive F et al. Am J Hum Genet (2022)	0.380	0.041	<0.001	1.46 [1.35-1.59]	SAS
metaPRS_CAD	PGS002262	Lu X et al. Eur Heart J (2022)	0.193	0.041	<0.001	1.21 [1.12-1.31]	SAS
PRSCS _{CHD}	PGS001780	Tamlander M et al. Commun Biol (2022)	0.420	0.042	<0.001	1.52 [1.4-1.65]	SAS
GBE_HC942	PGS000962	Tanigawa Y et al. PLoS Genet (2022)	0.180	0.040	<0.001	1.2 [1.11-1.29]	SAS
ldpred_cad	PGS002244	Mars N et al. Cell Genom (2022)	0.301	0.042	<0.001	1.35 [1.25-1.47]	SAS
PRS ₂₀₂₂	PGS003356	Aragam KA et al. Nat Genet (2022)	0.469	0.042	<0.001	1.6 [1.47-1.73]	SAS
GPS _{Mult}	-	-	0.606	0.042	<0.001	1.83 [1.69-1.99]	SAS

The odds ratio for prevalent coronary artery disease (CAD) risk per standard deviation of the polygenic score and 95% confidence interval were validated in a logistic regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry in a holdout cohort of individuals of the Genes & Health study using prior published scores from the Polygenic Score Catalog. SAS: South Asian ancestry.

Table 8: Model C-statistics by ancestry in the UK Biobank Study

Ancestry	All	African	East Asian	European	South Asian
Age+Sex	0.71 (0.706-0.715)	0.708 (0.666-0.75)	0.775 (0.694-0.856)	0.708 (0.703-0.712)	0.712 (0.692-0.732)
PCE	0.739 (0.735-0.744)	0.749 (0.707-0.791)	0.803 (0.71-0.895)	0.739 (0.734-0.743)	0.739 (0.717-0.76)
PCE+GPS_{Mult}+PCE*GPS_{Mult}	0.763 (0.759-0.768)	0.753 (0.712-0.794)	0.882 (0.843-0.921)	0.762 (0.758-0.767)	0.764 (0.743-0.784)
QRISK3	0.746 (0.741-0.75)	0.747 (0.698-0.796)	0.811 (0.73-0.893)	0.744 (0.74-0.749)	0.745 (0.722-0.769)
QRISK3+GPS_{Mult}+QRISK3*GPS_{Mult}	0.769 (0.764-0.773)	0.759 (0.712-0.806)	0.882 (0.834-0.929)	0.768 (0.763-0.772)	0.777 (0.756-0.799)


C-statistics stratified by ancestry are based on 10-year follow-up events from Cox regression models of listed variables, the first ten principal components of genetic ancestry, and genotyping array. ACC/AHA Pooled Cohort Equations (PCE) and QRISK3 include age and sex variables in their risk estimation.

Table 9: Model net reclassification by ancestry in the UK Biobank Study

NRI		Status	All	African	East Asian	European	South Asian
Categorical	PCE	Full	0.070 (0.059-0.082)	0.010 (-0.016-0.035)	0.000 (-0.008-0.176)	0.073 (0.063-0.081)	0.067 (0.019-0.147)
		Cases	0.081 (0.069-0.094)	0.010 (-0.016-0.034)	0.000 (0.000-0.179)	0.083 (0.074-0.092)	0.102 (0.043-0.188)
		Noncases	-0.011 (-0.012 - -0.009)	0.00 (-0.003-0.002)	0.000 (-0.008-0.003)	-0.011 (-0.012-0.009)	-0.035 (-0.053-0.018)
	QRISK3	Full	0.034 (0.028-0.040)	0.011 (-0.014-0.058)	-0.001 (-0.003-0.002)	0.036 (0.029-0.044)	0.025 (-0.011-0.101)
		Cases	0.038 (0.032-0.045)	0.012 (-0.012-0.059)	0.000 (0.000-0.000)	0.040 (0.033-0.049)	0.035 (-0.004-0.124)
		Noncases	-0.004 (-0.005 - -0.003)	-0.001 (-0.003-0.001)	-0.001 (-0.003-0.002)	-0.005 (-0.006-0.004)	-0.011 (-0.023-0.003)
Continuous	PCE	Full	0.405 (0.379-0.424)	0.057 (-0.211-0.291)	0.427 (-0.249-0.849)	0.412 (0.388-0.431)	0.366 (0.269-0.463)
		Cases	0.200 (0.182-0.215)	-0.026 (-0.245-0.184)	0.285 (-0.402-0.599)	0.206 (0.186-0.221)	0.175 (0.104-0.257)
		Noncases	0.205 (0.197-0.213)	0.084 (-0.012-0.183)	0.142 (-0.007-0.347)	0.207 (0.195-0.217)	0.191 (0.158-0.233)
	QRISK3	Full	0.395 (0.373-0.418)	0.173 (-0.207-0.673)	0.300 (-0.338-0.780)	0.403 (0.377-0.426)	0.355 (0.232-0.456)
		Cases	0.195 (0.177-0.214)	0.059 (-0.165-0.443)	0.164 (-0.496-0.594)	0.201 (0.183-0.218)	0.173 (0.073-0.246)
		Noncases	0.200 (0.192-0.210)	0.114 (-0.013-0.406)	0.137 (-0.015-0.383)	0.202 (0.193-0.210)	0.183 (0.138-0.243)


The improvement in the predictive performance of the addition of the GPS_{Mult} to the ACC/AHA Pooled Cohort Equations (PCE) or QRISK3 was evaluated in each ancestry using continuous and categorised net reclassification improvement (NRI), with a risk probabilities threshold of 7.5% obtained with Kaplan-Meier estimates for a period of 10 years and confidence intervals (95%) obtained from 100-fold bootstrapping.

Figure 1: Sequential improvements in R^2 with GPS_{Mult} in the UK Biobank Study




The proportion of phenotypic variance explained by the polygenic score predicting coronary artery disease (CAD) was calculated in the UK Biobank European ancestry validation cohort for each GPS score using the A: Nagelkerke's pseudo- R^2 metric, as the difference of the full model inclusive of the polygenic score plus age, sex, genotyping array, and the first ten principal components of ancestry minus R^2 for the covariates alone; and B: logit-liability R^2 metric, as described elsewhere.¹⁹ GPS₂₀₁₈ denotes previously published polygenic score for CAD.²⁰ >3-fold larger CAD GWAS designates metrics for polygenic score generated using summary statistics from the most recent Coronary Artery Disease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics consortium analysis (CARDIOGRAMplusC4D) excluding the UKBB. Multi-ancestry CAD GWAS refers to the polygenic score generated by combining ancestry-specific polygenic scores generated using discovery data from Genes & Health, Biobank Japan, Million Veteran Program, FinnGen, and CARDIOGRAMplusC4D (excluding UKBB). GPS_{Mult} designates polygenic score for CAD designed with summary statistics from multiple ancestries and multiple CAD-related traits.

Figure 2: GPS_{Mult} performance by sex and age subgroups




The odds ratio for prevalent coronary artery disease (CAD) risk per standard deviation of the GPS_{Mult} was assessed in a logistic regression model adjusted for age, sex, genotyping array, and the first ten principal components of genetic ancestry in the European ancestry validation dataset of the UK biobank stratified by sex and age subgroups.

Figure 3: Equivalents of increased risk for incident coronary artery disease event identified by high GPS_{Mult} in the UK Biobank Study




A: Cumulative incidence of coronary artery disease (CAD) events over length of follow-up stratified by presence of prior CAD, no prior CAD with GPS_{Mult} in the bottom 97% or top 3% of the population, estimated using Cox proportional-hazards regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry in the European ancestry UK Biobank validation dataset. B: Cumulative incidence of coronary artery disease (CAD) events over length of follow-up stratified by presence of prior peripheral artery disease (PAD) or no prior PAD with GPS_{Mult} in the bottom 92% or top 8% of the population, estimated using Cox proportional-hazards regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry in the European ancestry UK Biobank validation dataset. C: Cumulative incidence of CAD events over length of follow-up stratified by presence of prior diabetes mellitus (DM) or no prior DM with GPS_{Mult} in the bottom 79% or top 21% of the population, estimated using Cox proportional-hazards regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry in the European ancestry UK Biobank validation dataset. D: Cumulative incidence of CAD events over length of follow-up stratified by presence of prior severe hypercholesterolemia (estimated untreated low-density lipoprotein cholesterol, LDL-C 190 mg/dL or higher), or no prior hypercholesterolemia with GPS_{Mult} in the bottom 72% or top 28% of the population, estimated using Cox proportional-hazards regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry in the European ancestry UK Biobank validation dataset.

Figure 4: Decrease in risk for incident coronary artery disease identified by low GPS_{Mult}




Cumulative CAD risk stratified by GPS_{Mult} in the bottom 5%, 5-9%, and 40-59% of the population, estimated using Cox proportional-hazards regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry in the European ancestry validation dataset of the UK Biobank Study. GPS: Genome-wide polygenic score.

Figure 5: Net reclassification for GPS_{Mult} and CAD risk enhancers over PCE 10-year risk estimates



Net reclassification of coronary artery disease (CAD) cases and non-cases achieved by established CAD risk enhancing factors and GPS_{Mult} when added to a baseline model of just the American Heart Association/American College of Cardiology Pooled Cohort Equations²¹ in the European ancestry validation dataset of the UK Biobank.

Figure 6: Association of GPS_{Mult} and risk factors with incident and recurrent coronary artery disease events



Hazards ratio per standard deviation (HR/SD) of variable of interest for incident disease assessed in individuals without prior coronary artery disease (CAD) followed for development of first CAD event with Cox proportional hazards regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry in the European ancestry validation dataset of the UK Biobank Study. Hazards ratio per standard deviation of variable of interest for recurrent disease assessed in individuals with prior CAD followed for development of recurrent CAD event with Cox proportional hazards regression model adjusted for age, sex, genotyping array, and the first ten principal components of ancestry. *LDL-C, HDL-C, and triglyceride values were adjusted for cholesterol-lowering medication status, as previously described.¹⁷ BP: Blood pressure. BMI: Body-mass index. HgbA1c: Glycated hemoglobin. LDL-C: Low-density lipoprotein cholesterol. HDL-C: High-density lipoprotein cholesterol.

References:

1. Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. 2021.05.24.21257377 Preprint at <https://doi.org/10.1101/2021.05.24.21257377> (2021).
2. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet* **53**, 1415–1424 (2021).
3. Huang, Q. Q. *et al.* Transferability of genetic loci and polygenic scores for cardiometabolic traits in British Pakistani and Bangladeshi individuals. *Nat Commun* **13**, 4664 (2022).
4. Kurki, M. I. *et al.* FinnGen: Unique genetic insights from combining isolated population and national health register data. 2022.03.03.22271360 Preprint at <https://doi.org/10.1101/2022.03.03.22271360> (2022).
5. Tcheandjieu, C. *et al.* Large-scale genome-wide association study of coronary artery disease in genetically diverse populations. *Nat Med* **1**–13 (2022) doi:10.1038/s41591-022-01891-3.
6. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015).
7. Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet* **50**, 1412–1425 (2018).
8. Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet* **52**, 680–691 (2020).
9. Spracklen, C. N. *et al.* Identification of type 2 diabetes loci in 433,540 East Asian individuals. *Nature* **582**, 240–245 (2020).
10. Hodgson, S. *et al.* Harnessing the power of polygenic risk scores to predict type 2 diabetes and its subtypes in a high-risk population of British Pakistanis and Bangladeshis in a routine healthcare setting. 2021.07.12.21259837 Preprint at

<https://doi.org/10.1101/2021.07.12.21259837> (2021).

11. Graham, S. E. *et al.* The power of genetic diversity in genome-wide association studies of lipids. *Nature* **600**, 675–679 (2021).
12. Klarin, D. *et al.* Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. *Nat Genet* **50**, 1514–1523 (2018).
13. Klarin, D. *et al.* Genome-wide Association Study of Peripheral Artery Disease in the Million Veteran Program. *Nat Med* **25**, 1274–1279 (2019).
14. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* **50**, 524–537 (2018).
15. Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: powering genetic discovery across human diseases. 2021.11.19.21266436 Preprint at <https://doi.org/10.1101/2021.11.19.21266436> (2021).
16. Wuttke, M. *et al.* A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nat Genet* **51**, 957–972 (2019).
17. Patel, A. P. *et al.* Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. *JAMA Netw Open* **3**, e203959 (2020).
18. Patel, A. P., Wang, M., Kartoun, U., Ng, K. & Khera, A. V. Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals. *Circulation* **144**, 410–422 (2021).
19. Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. *Genet Epidemiol* **36**, 214–224 (2012).

20. Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).
21. Goff David C. *et al.* 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. *Circulation* **129**, S49–S73 (2014).